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Abstract
Nuclear factor kappa-B (NF-kB) activates multiple genes with overlapping roles in cell proliferation, inflammation and
cancer. Using an unbiased approach we identified human CDK6 as a novel kinase phosphorylating NF-kB p65 at serine 536.
Purified and reconstituted CDK6/cyclin complexes phosphorylated p65 in vitro and in transfected cells. The physiological
role of CDK6 for basal as well as cytokine-induced p65 phosphorylation or NF-kB activation was revealed upon RNAi-
mediated suppression of CDK6. Inhibition of CDK6 catalytic activity by PD332991 suppressed activation of NF-kB and TNF-
induced gene expression. In complex with a constitutively active viral cyclin CDK6 stimulated NF-kB p65-mediated
transcription in a target gene specific manner and this effect was partially dependent on its ability to phosphorylate p65 at
serine 536. Tumor formation in thymi and spleens of v-cyclin transgenic mice correlated with increased levels of p65 Ser536
phosphorylation, increased expression of CDK6 and upregulaton of the NF-kB target cyclin D3. These results suggest that
aberrant CDK6 expression or activation that is frequently observed in human tumors can contribute through NF-kB to
chronic inflammation and neoplasia.
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Introduction
The transcription factor nuclear factor kappa B (NF-kB)
comprises homo-or heterodimeric combinations of five DNA-
binding subunits which regulate the expression of a large number
of genes in multiple physiological or pathophysiological conditions
such as inflammation, immune reactions or cancer [1]. NF-kB
activation is prevented by cytosolic retention by inhibitor of NF-
kB (IkB) proteins. Phosphorylation-dependent proteolytic degra-
dation of IkBs in response to inducers such as proinflammatory
cytokines, in particular IL-1 or TNFa, is followed by nuclear
translocation and DNA binding of NF-kB subunits. Thousands of
potential DNA binding sites have been described across the
genome [2]. Hence, NF-kB activity needs to be spatially,
kinetically and quantitatively controlled to allow precise expression
of its target genes [1]. Within the nuclear compartment, there is an
additional layer of regulation of NF-kB activity provided by
numerous posttranslational modifications (PTMs) including ubi-
quitination, acetylation and phosphorylation [3]. As an example
for the latter, the transcriptionally most potent subunit of NF-kB,
p65, is phosphorylated at amino acids 254, 276, 311, 435, 468,
505, 529, 536 by a number of different protein kinases [3–6].
PTMs of p65 can regulate interaction with coactivators [7],
corepressors [8], promoter-bound degradation [9] and interactions
with the basal transcriptional machinery [10]. According to the
NF-kB barcode hypothesis that was recently suggested by us the
differential modifications of the DNA-binding subunits generate
distinct patterns that function to direct transcription in a highly
target gene-specific fashion [11].
There is also clear evidence for a pivotal role of NF-kB in
chronic inflammation and cancer [12,13]. In this scenario, NF-kB
is activated by cytokines such as IL-1 or TNFa released from cells
of the inflammatory tumor microenvironment or by constitutively
activated intracellular upstream regulators of IkB kinases (IKKs)
within cancer cells. Subsequently, NF-kB induces numerous
inflammatory target genes such as chemokines, IL-6 or matrix
metallo proteinases which can all be tumor-promoting [14].
However, NF-kB also directly affects cell proliferation by
modulating expression of cell cycle-regulatory proteins such as
D-type cyclins [15–17]. Further, IkBa controls NF-kB transcrip-
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tion factor complex p52/RelB in G1 to S-phase progression [18],
and p65 interacts in an inducible manner with cell cycle inhibitor
p16INK4a [19]. In contrast, a reciprocal influence of cell cycle
signaling pathways on NF-kB-dependent gene expression has been
elusive although there is evidence that NF-kB activity and
recruitment to proliferative target genes fluctuates during the cell
cycle [12].
Cyclin-dependent kinase 6 (CDK6) and its close homologue
CDK4 are members of the family of vertebrate cdc-2 related
kinases [20,21]. As they were shown to partner with D-type cyclins
and to possess retinoblastoma protein (Rb) kinase activity [22]
their main function was considered to relieve Rb-mediated
transcriptional repression and to promote G1 to S transition
during interphase of the cell cycle [23,24]. However, genetic
evidence has challenged the classical role of CDK4 and CDK6 in
G1/S cell cycle transition, as individual or combined deletion of
CDK4 and CDK6 remains without impact on cell proliferation
[25–27]. Moreover, CDK4-activation can occur independent
from CDK6 by an unknown upstream proline-directed kinase
[28]. This has led to speculations that CDK4 and CDK6 might
have yet to discover distinct and unique effector functions that are
unrelated to their major substrate Rb and to their role in cell cycle
transition [29].
Here we describe the identification of human CDK6 as a NF-
kB p65 Ser536 phosphorylating kinase using an unbiased
approach. The role of CDK6 for p65 Ser536 phosphorylation
was confirmed by gain-of-function and loss-of-function approach-
es. A transgenic mouse model allowing the lymphocyte-specific
activation of CDK6 activity showed increased p65 Ser536
phosphorylation and tumor formation.
Results
Identification of CDK6 as a p65 NF-kB Kinase
We have previously found five distinct protein kinases that
phosphorylate the transcriptionally most active NF-kB subunit p65
at Ser536 [4]. They were discriminated based on their elution
pattern from ion exchange chromatography of cell extracts of
untreated and IL-1-treated cells. All of these kinases were highly
specific for Ser536 as they phosphorylated a GST-p65 fusion
protein containing amino acids 354-551, but not versions
containing Ser536 mutated to alanine [4]. While the p65 Ser536
phosphorylating kinases IKKa, IKKb, TBK1 and IKKe all eluted
at higher NaCl concentrations, an unknown Ser536-specific
enzymatic activity eluted from the column very early [4]. Here,
we report the purification and identification of this enzyme
(Fig. 1A). Extracts from IL-1-treated HeLa cells were chromato-
graphed as shown in Fig. 1A. Peak fractions from Resource Q
were pooled and further chromatographed on a phenyl sepharose
column. Fractions were assayed using a non-radioactive in vitro
kinase assay and recombinant GST-p65 (aa 354–551) as substrate
(Fig. 1B) exactly as previously described [4]. The fractions
containing active p65 Ser536 phosphorylating kinase were pooled,
further purified by size exclusion using an ultrafiltration device,
concentrated and then separated by SDS-PAGE as shown in
(Fig. 1A). This material contained 45 protein bands that stained
with SyproRuby (Fig. 1C). Mass spectrometry on tryptic peptides
of all proteins present in the sample showed that the fraction
contained only one protein kinase, as revealed by the presence of
three peptides covering the amino acid sequence of cyclin-
dependent kinase 6 (CDK6) (Fig. 1D). Since there are only a few
well established substrates for CDK6 such as retinoblastoma
protein (Rb) [22,24], histone H1 [30], Bcl-2 [31], Runx [32] and
nucleophosmin [33] we performed additional in vitro experiments
with the purified fractions to confirm that CDK6 is indeed a direct
p65 NF-kB kinase. Antibodies against CDK6 validated the
presence of the protein in the phenyl sepharose fractions
containing Ser536 kinase activity (Fig. 1B, E). CDK6 immuno-
purified from these phenyl sepharose fractions displayed p65
phosphorylation as assessed by in vitro kinase assays whereas IgG
antibodies did not precipitate any p65 NF-kB kinase activity
(Fig. 1E).
CDK6 requires association with cyclins D1-D3 and additional
phosphorylations by the cyclin-activating kinase (CAK) complex
for full activation [28]. In addition, a viral (v)-cyclin encoded by an
open reading frame of Kaposi sarcoma herpesvirus (KSHV) was
shown to associate with CDK6 as well as with its close homologue
CDK4 [34]. V-cyclin-bound CDK6 has increased activity and is
insensitive to inhibition by the CDK inhibitor p16INK4a
[30,35,36]. To find out if any of the known CDK6/cyclin
complexes phosphorylate NF-kB p65 at Ser536, CDK6, cyclins
D1–D3 and v-cyclin were expressed in E. coli (Fig. 2A, upper
panel). Kinase activity of CDK6 in complex with these proteins
was assessed using an established in vitro coupled kinase assay
system by which endogenous CAK activity is provided by addition
of cell extracts [37]. After removal of cell extracts, activated GST-
CDK6/GST-cyclin complexes were washed to remove contam-
inating kinases and were used for non-radioactive in vitro kinase
assays. GST mixed with cell extracts or kinase assays without any
addition of GST or GST-CDK6/GST-cyclin complexes were
used as negative controls to determine unspecific background
signals of the non-radioactive kinase assay. All four activated
CDK6/cyclin complexes showed increased in vitro phosphoryla-
tion of p65 at Ser536 above background signals providing further
evidence for CDK6 as a Ser536-specific NF-kB kinase (Fig. 2A,
lower panel). Side-by side comparison of kinase activities showed
that GST-v-cyclin/GST-CDK6 complexes were slightly more
active than GST-cyclinD1/GST-CDK6 complexes (Fig. 2A, lower
right panel). To get further independent evidence for CDK6 as a
direct Ser536 kinase we used a recombinant CDK6/cyclinD1
complex from baculovirus-infected Sf9 insect cells which accord-
ing to the commercial supplier contains a nearly homogenously
purified CDK6/cyclin D1 complex. This kinase preparation also
phosphorylated Ser536 in vitro in a time- and dose-dependent
manner (Fig. 2B). To further establish CDK6 as a Ser536 kinase in
intact cells we ectopically expressed wild type CDK6 or a recently
published novel CDK6 mutant which shows increased kinase
activity without the requirement of CAK [28] together with cyclin
D3 or v-cyclin and assessed the phosphorylation level of
endogenous p65 and of the CDK6 substrate Rb. Both, wild type
CDK6 and CDK6 S178P increased phosphorylation of p65 NF-
kB at Ser536 as well as phosphorylation of Rb (Fig. 2C). The
CDK6 mutant CDK6 S178P was slightly more active in
phosphorylating p65 Ser536 when compared to the wild type
kinase. Furthermore CDK6 S178P kinase activity was highest
when it was in conjunction with v-cyclin (Fig. 2C). Collectively, the
results shown in Fig. 1 and 2 provide strong evidence for CDK6 as
a direct p65 kinase by four independent approaches.
RNAi-mediated Suppression of CDK6 Affects Cytokine-
inducible and Constitutive Phosphorylation of NF-kB p65
We then used RNA-interference to define the functional
relevance of CDK6 for TNF-induced p65 phosphorylation. In
non-transformed MDCK cells, siRNA-mediated suppression of
CDK6 partially reduced cytokine-triggered p65 Ser536 phosphor-
ylation (Fig. 3A). CDK6 knockdown also led to a delayed and
reduced nuclear translocation of p65 (Fig. 3B) which is in line with
our previous observation that phosphorylation of p65 Ser536 is
CDK6 Phosphorylates NF-kappaB p65
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modulating the nuclear import of p65 [38]. As CDK6 activity is
known to be highest in G1 [22] we also tested the requirement of
CDK6 for p65 Ser 536 phosphorylation in synchronized tumor
cells. In arrested HeLa cells, phospho-Ser536 levels were low but
were upregulated by about twofold by serum-mediated cell cycle
release (Fig. 3C). IL-1 treatment of cells stimulated p65 Ser536
phosphorylation by five- to six-fold and this effect was slightly
enhanced by serum treatment (Fig. 3C). In a stably transfected
HeLa cell line with strong CDK6 knockdown, the IL-1-induced
increase in Ser536 phosphorylation was inhibited by 30–40% with
suppression of the IL-1 effect in G1-released conditions reaching
statistical significance (Fig. 3C). Thus the data shown in Fig. 3A to
C reveal a contribution of CDK6 to total Ser 536 phosphorylation
in intact cells in two cell culture model systems. As CDK6
suppression in these experiments was at least 90%, the remaining
Ser536 phosphorylation is most likely due to the activity of other
p65 kinases such IKKa/ß. While these experiments show the
contribution of CDK6 for cytokine-inducible p65 Ser536 phos-
phorylation, it was also of interest to investigate whether CDK6
contributes to constitutive p65 phosphorylation as it occurs for
Figure 1. Identification of CDK6 as a NF-kB p65 Ser536 kinase. (A) Purification scheme. (B) HeLa cells were stimulated with IL-1 for 10 min,
lyzed and proteins fractionated by ion exchange chromatography (IEX) on a Resource Q column as previously described [4] followed by hydrophobic
interaction chromatography (HIC) on a phenyl sepharose column. Proteins were eluted from phenyl sepharose with a decreasing salt gradient (1 M to
0 M) and individual fractions assayed for in vitro phosphorylation of Ser536 using GST-p65354- 551 as substrate. Phosphorylated p65 and total p65
protein substrate were detected by immunoblotting. The graph shows quantification of Ser536 kinase activity relative to the starting material (IEX
pool). (C) Proteins of fractions 16–19 from repeated runs purified up to the HIC step were pooled, concentrated, precipitated and separated in a
single lane by SDS PAGE. Proteins were visualized with SyproRuby and 48 segments contained in 45 bands were excised and analyzed by mass
spectrometry. Two bands identified as CDK6 are indicated by arrows; the positions of molecular weight marker proteins are indicated. (D) Peptide
coverage of human CDK6 by three different peptides (underlined) as identified by mass spectrometry. (E) p65 Ser536 kinase activity was purified up
to the phenyl sepharose step as shown in (B). Upper panel: fractions were analyzed for CDK6 antigen by immunoblotting. Lower panel: fractions 16–
19 were pooled and immunoprecipitated with anti CDK6 antibody or control IgG. Immunopurified material was split and analyzed by radioactive
in vitro kinase assay (ka) using GST-p65354- 551 as substrate. Reaction mixtures were separated by SDS-PAGE, stained with Coomassie Brilliant Blue
(CBB) and autoradiographed to detect phosphorylation of GST-p65354- 551. The other part of the immunoprecipitate was analyzed by immunoblotting
(IB) for the presence of CDK6.
doi:10.1371/journal.pone.0051847.g001
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example in tumor cells. To address this question we utilized the
patient-derived primary effusion lymphoma (PEL) cell line BC-3
[39]. These KSHV-infected B-cell lymphomas critically depend
on constitutive NF-kB activity that mediates enhanced production
of lymphoma cell survival factors such as IL-6 [40]. These cells
also constitutively express v-cyclin that specifically activates
CDK6. CDK6 was silenced by expression of a lentivirally
delivered specific shRNA and knockdown efficiency was controlled
by Western blotting (Fig. 3D). After fractionation of cells into
cytosolic (c) and soluble (ns) and insoluble nuclear (ni) fractions, the
status of Ser536 phosphorylated p65 was analyzed by immuno-
blotting. Silencing of CDK6 resulted in a reduced p65 phosphor-
ylation signal in the cells analyzed by immunofluorescence
(Figure 3E; right top panel). A modest reduction in p65
phosphorylated at Ser536 and in expression of the NF-kB target
gene cyclin D3 was also detected in the cytosolic and the soluble
nuclear compartments following CDK6 silencing (Fig. 3D). These
results suggest that (i) CDK6 also contributes to permanent p65
Ser536 phosphorylation occurring in tumor cells with constitutive
NF-kB activity and (ii) in such cells CDK6 regulates p65
phosphorylation both, in the cytosol and in the nucleus.
CDK6 Regulates NF-kB-dependent Target Gene
Expression
To test a possible impact of CDK6 on NF-kB-triggered gene
transcription, HEK293IL-1R cells were transiently transfected
with vectors encoding two different shRNA duplexes directed at
CDK6 or a vector control. Both of them suppressed CDK6 but
not CDK4 (Fig. 4A). IL-1-triggered activity of a NF-kB-dependent
reporter gene was largely inhibited by the two different shRNAs
(Fig. 4A). The importance of protein kinases for signaling can be
either due to their enzymatic activity, or alternatively to their
function as a scaffold, as exemplified by the Aurora A kinases [41].
As the kinase activity of CDK6 (and of CDK4) can be inhibited by
the ATP-competitve inhibitor PD332991 [42] we assessed the
effect of this inhibitor on IL-1-induced NF-kB activation and
mRNA expression of endogenous genes. PD332991 partially
inhibited IL-1-induced NF-kB-dependent reporter gene activation
(Fig. 4B). The compound also inhibited TNF-inducible expression
of IL-8, CXCL3, CCL20, IL-6, PTGS2 and NFKBIZ expression
by about 50% (Fig. 4C), whereas it more weakly affected TNF-
induced expression of IkBa and had no impact on inducible cyclin
D1 expression (Fig. 4C). These data suggest that the catalytic
activity of CDK6 is required for expression of a range of NF-kB
dependent inflammatory target genes in a gene specific-manner.
Figure 2. A purified and reconstituted CDK6/cyclin complex phosphorylates NF-kB p65 Ser 536. (A) GST fusion proteins of cyclins D1 to
D3, viral (v)-cyclin and CDK6 were expressed and purified in E.coli. Comparable amounts of GST, GST-cyclins and GST-CDK6 as judged from
immunoblotting analysis (upper panel) were mixed with HeLa cell extract to provide CDK-activating kinase CAK as described in [37]. Kinase reactions
were performed by addition of ATP. Then, GST alone or activated CDK6/cyclin complexes were purified by addition of GSH-beads, washed and used
to phosphorylate the GST-p65354- 551 substrate in vitro. Phosphorylation of p65 Ser536 was detected by immunoblotting of kinase reaction mixtures
(lower panel). Recombinant GST protein or kinase reactions without GST-CDK6/cyclin complexes (labeled no kinase) were used to determine
background signals. (B) Increasing amounts of a recombinant CDK6/cyclin D1 complex purified to homogeneity from baculovirus-infected insect cells
was mixed with GST-p65354- 551 and the kinase reaction was allowed to proceed over time. Phosphorylation of p65 at Ser536 was detected by
immunoblotting. (C) HeLa cells were transfected with the expression vectors for wild type (wt) CDK6, a gain of function mutant (CDK6-S178P) and
cyclin D3 or viral (v)- cyclin. 24 h later cells were lysed and phosphorylation of p65 and of Rb and expression of transfected proteins was analyzed by
immunoblotting of cell extracts using the indicated antibodies.
doi:10.1371/journal.pone.0051847.g002
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Figure 3. CDK6 contributes to basal and TNF-inducible p65 Ser536 phosphorylation. (A) MDCK cells were treated for 24 h with siRNAs
directed against CDK6 or adequate scrambled controls followed by treatment with TNFa as indicated. Total cell extracts were analyzed for
phosphorylation of p65 and expression of the indicated proteins by immunoblotting. Numbers indicate relative levels of p65 Ser536 phosphorylation.
CDK6 Phosphorylates NF-kappaB p65
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v-cyclin Activates NF-kB through CDK6 and Induces
Tumors in Lymphoid Organs
We then investigated a functional role of CDK6 in NF-kB
activation by a gain-of-function approach resembling pathophys-
iological conditions where CDK6 is overexpressed or constitu-
tively activated [26]. Towards this goal we coexpressed v-cyclin or
cyclin D1 together with CDK6 and measured the impact on NF-
kB reporter gene activity. Ectopically expressed CDK6 alone
caused a twofold increase in NF-kB activation (Fig. 5A). However,
coexpression of increasing amounts of v-cyclin allowed a dose-
dependent increase of NF-kB-dependent transcription (Fig. 5A).
To investigate whether NF-kB p65 phosphorylation contributes to
the stimulatory effect of CDK6 on NF-kB activity p65-deficient
murine embryonic fibroblasts (MEFs) were transfected to express
wild type p65 or the non-phosphorylatable p65 S536A mutant
along with v-cyclin/CDK6 and two different reporter genes. The
NF-kB-dependent reporter gene was stimulated by threefold upon
expression of v-cyclin and CDK6 (Fig. 5B upper), conditions that
also trigger p65 Ser536 phosphorylation. No activation was seen in
the absence of p65, and the cells reconstituted with the p65
Ser536A mutant showed impaired basal and v-cyclin/CDK6-
induced NF-kB activation. In contrast, a reporter gene under the
control of the cyclin D1 promoter containing a functional NF-kB
binding site [16,17,17] showed a different behavior, as p65 Ser536
phosphorylation was of minor relevance for CDK6/v-cyclin-
triggered gene induction (Fig. 5B lower).
To address the role of CDK6/v-cyclin complex in p65 Ser536
phosphorylation and NF-kB activation under pathophysiological
conditions, we analyzed Em-v-cyclin transgenic mice. In this
model, v-cyclin expression is targeted to B- and T-lymphocyte
compartments by a tissue specific promoter leading to develop-
ment of splenic and thymic tumors in about 10–20% of these mice
[43–45]. Indeed, increased levels of phosphorylated p65 Ser536
were detected in lymphocytes from pre-tumorigenic thymi and
thymic tumors (Fig. 6A) as well as in pre-tumorigenic spleens
(Fig. 6B) of the v-cyclin transgenic animals as compared to the
thymic or splenic lymphocytes isolated from non-transgenic
littermates. Importantly, the v-cyclin expressing transgenic mice
demonstrating increased p65 Ser536 phosphorylation (Fig. 6A,B)
also developed lymphoid tumors (Fig. 6C). Increased p65 Ser536
phosphorylation in the tumors correlated with increased levels of
CDK6 and the NF-kB target gene cyclin D3 (Fig. 6A). These data
strengthen the role of CDK6 and its viral cyclin partner in the
phosphorylation of p65, and suggest the occurrence of increased
NF-kB activity in the affected organs of the Em-v-cyclin transgenic
mouse.
Discussion
NF-kB p65 Ser535 phosphorylation is executed by a surpris-
ingly large number of different kinases and phosphatases [46]
raising the possibility that the various kinases have partially
redundant functions and are of special relevance in specific
signaling pathways. It is presently not clear whether CDK6
phosphorylates p65 in the cytosol or in the nucleus, as both
proteins occur in these two compartments. Whereas Ser536
phosphorylation of cytosolic p65 will increase the efficiency of
nuclear import (see Fig. 3B and [38]) this phosphorylation will
serve other purposes in the nucleus. NF-kB p65 Ser536
phosphorylation regulates interaction with corepressors and
coactivators such as TAFII31, one of the subunits of TFIID thus
directly contributing to increased transactivation of genes like IL-8
[4]. It is generally observed that posttranslational modifications of
the NF-kB DNA-binding subunits have no global effects on
transcription but rather serve to control gene expression in a
highly target gene specific manner [11,47]. This raises the
possibility that NF-kB kinases can also modify further substrates
(chromatin components, coregulatory proteins) relevant for the
expression of inflammatory genes. It will therefore be interesting to
study in the future whether the role of CDK6 for a subset of NF-
kB-dependent target genes relies entirely on its ability to
phosphorylate Ser536 or whether also other mechanisms are
involved. Another implication of this study stems from the natural
fluctuation of CDK6 kinase activity which is maximal at the G1/S
transition. This raises the possibility that the expression of CDK6-
dependent proinflammatory genes is differentially regulated in
various cell cycle phases.
Chronic inflammation and cancer are intimately linked
underscoring the importance to unravel the underlying mecha-
nisms of molecular and physiological cross-talk [13,14]. The
CDK6 gene is frequently amplified or overexpressed in a variety of
human tumors [29,48] such as glioblastoma [49] and human
lymphoid malignancies [48,50,51]. CDK6 or its close counterpart
CDK4 also act as oncogenes in tumors expressing mutant versions
or devoid of cell cycle inhibitors such as p16INK4a [52]. In most
cases, the contribution of CDK6 to tumor phenotypes has been
assessed in conjunction with CDK4, particularly in studies using
PD332991 which inhibits both kinases [42]. While there is ample
evidence that the transforming properties of CDK4/6 are
transmitted through phosphorylation of Rb [26], CDK4/6 can
also contribute to tumorigenesis in the absence of Rb [53] by
phosphorylating as yet unidentified substrates [54]. In line with
this, a large number of additional substrates containing at least two
CDK consensus sites were recently identified in vitro [55]. Ser536
of p65 NF-kB is not part of the classical CDK consensus site Ser/
Thr-Pro-X-Lys/Arg. A recent large scale in silico analysis
(B) The experiment was done as in (A) with the exception that cells were fractionated in nuclear and cytosolic extracts. Extracts were further analyzed
for the occurrence of nuclear p65, relative levels are indicated by numbers. Suppression of CDK6 in the cytoplasm was validated by CDK6 antibodies
and quantified. Actin and HDAC1 detection served to control the purity of the fractions. (C) A Hela cell line stably transfected with shRNAs directed
against CDK6 (shCDK6, K06) or cells stably transfected with pSuper-Puro (vector) were subjected to cell cycle arrest by serum deprivation for 48 h
(arrest). Thereafter cells were released for 6 h by addition of 20% serum (G1 release). In addition, cells were treated with IL-1 (10 ng/ml) for 30 min as
indicated. Total cell extracts were separated by SDS-PAGE in two sets on one gel and were transferred to one membrane. One half of the membrane
was probed with antibodies against phospho-Ser536, CDK6, CDK4 and b-actin. The other half was probed with anti p65 antibodies. Numbers indicate
relative phosphorylation of p65 or relative protein levels of p65 and CDK6. The graph shows the mean +/2 s.e.m. of relative Ser536 phosphorylation
normalized to p65 total protein as determined in three independent experiments. The asterisk indicates significant differences (p,=0.018) as
determined by paired t-test. (D) Naturally KSHV-infected primary effusion lymphoma (PEL) cells [39] were stably infected with lentiviruses encoding
shRNAs directed against CDK6 or scrambled shRNA controls. Cells were fractionated into cytosolic (c), nuclear soluble (ns) and nuclear insoluble (ni)
fractions. These extracts were analyzed by immunoblotting with the indicated antibodies. Tubulin was used as a loading control for cytosolic and
nuclear soluble fractions and SP1 as a marker for the nuclear insoluble fraction. Numbers indicate relative levels of phospho-Ser536 p65, cyclinD3 and
CDK6. (E) PEL cells silenced for CDK6 expression as described in (D) were analyzed by indirect immunofluorescence for p65 and p65 Ser536
phosphorylation with specific antibodies, nuclear DNA was revealed by DAPI staining.
doi:10.1371/journal.pone.0051847.g003
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concluded that even the minimal CDK motif Ser/Thr-Pro is
equally often found in CDK6 substrates as well as in non-
substrates underscoring the difficulty in predicting CDK6 phos-
phorylation sites [56]. These authors also found that CDKs are
more likely to phosphorylate Ser/Thr residues in flexible,
unstructured regions of proteins [56]. The p65 transactivation
domain containing Ser536 adopts such an unstructured confor-
mation [57]. Hence, our data suggest that Ser536 of p65
represents a novel, unusual CDK6 phosphorylation site. Such a
phenomenon has been found for other proline-directed kinases,
e.g. Ser423 in the motif Ala-His-Ser-Ala of TAB1 is phosphor-
ylated by p38 MAPK [58]. In addition to having substrates other
than Rb, there is also increasing evidence for functional differences
between CDK4 and CDK6 [28,50,54,59,60]. Thus, CDK6 may
affect uncontrolled proliferation during tumor development by
Rb-independent mechanisms and accordingly our study unraveled
a novel connection between CDK6 and NF-kB. Depending on the
underlying genomic alterations, p65 transactivation activity may
be increased by a variety of oncogenic kinases such as IKKe [61]
or CDK6 as shown in this study. This predicts that increased
abundance or activity of CDK6 will amplify both, inflammation
and tumor progression.
Figure 4. Gene-specific regulation of NF-kB target genes by CDK6. (A) HEK293IL-1R cells were transiently transfected with a vector directing
the synthesis of two different shRNA duplexes directed at CDK6 or an empty vector control along with a NF-kB-dependent reporter gene and the
SV40-ß gal vector to allow for normalization. After 24 h, cells were stimulated for 4 h with IL-1a(10 ng/ml, black bars) or left untreated (white bars).
Cells were lysed and luciferase activity was normalized for co-transfected SV40-promoter driven ß-galactosidase. The graph shows the mean
luciferase activity +/2 s.e.m. from three independent experiments performed in duplicates relative to the vector control. (B) HEK293IL-1R cells were
transiently transfected with empty vector, NF-kB (3) luc and SV40-ß gal. After 24 h cells were pretretreated with 10 mM PD332991 and then further
stimulated for 4 h with IL-1a(10 ng/ml) or left untreated. Shown is the mean luciferase activity +/2 s.e.m. from two independent experiments. (C)
HeLa Fucci cells were arrested for two days and then left untreated or were treated with 10 mM PD332991 (hatched bars) for 30 min followed by
30 min TNFa (20 ng/ml) as indicated. Thereafter, total RNA was prepared and analysed for the expression of the indicated mRNAs by RT-qPCR. Data
show the mean –fold change +/2 s.e.m. from two independent experiments performed in duplicate. The asterisk indicates significant differences
(p,= 0.05) as determined by paired t-test.
doi:10.1371/journal.pone.0051847.g004
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Materials and Methods
Cell Lines
HeLa cells were from ATCC and HEK293 cells stably
expressing the IL-1 receptor (HEK293IL-1R) have been described
[4,62]. HeLa Fucci cells were from A. Miyawaki [63]. NF-kB p65-
deficient murine embryonic fibroblasts (MEFs) and cells stably
reconstituted with p65 or p65 (Ser536A) were from H. Nakano
[64]. Cells were cultured in Dulbecco’s modified Eagle’s medium,
complemented with 10% fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin. The BC-3 PEL cell
line [33,65] was kindly provided by E. Cesarman (Cornell Medical
College, NY) and cultured as described previously [44]. MDCK
cells (European Collection of Cell Cultures) were cultured in
RPMI 1640 medium (PAA Laboratories) supplemented with 10%
fetal calf serum and penicillin/streptomycin. All cell lines were
kept in a humid atmosphere at 37uC with 5% CO2.
Materials
Recombinant human TNFa was from R&D Systems or
Hoelzel. IL-1a was made as described [4]. PD332991 was a gift
from Pfizer or was purchased from Selleck Chemicals. Recombi-
nant CDK6/cycD1 complex (Product No.: 0051-0143-1, ProQi-
nase) was made in Sf9 cells and purified to near homogeneity as
judged by Coomassie staining and western blotting by the
manufacturer. Antibodies against the following proteins/peptides
were used: actin (JLA20, Calbiochem) or (Santa Cruz (sc)-1616),
CDK4 (C22, sc-260), CDK6 (C21, sc-177, DCS-90, sc-56282),
GST (Z5, sc459), cyclin D1 (M20, sc-718), SP-1 (PEP2, sc-59),
cyclin D3 (2936, Cell Signaling (c.s.)), P-Ser536 p65 (3031, 3033
(93H1), 3036 (7F1), c.s.), p65 (C-20, sc-109, sc-372, F-6, sc-8008),
mouse IgG (sc-2025), rabbit IgG (sc-2027), P-SS807/811 Rb
(9308, c.s.), tubulin (TU-02, sc-8035) or T4026 or GTU-88
(Sigma), HA, (clone 12CA5, Roche), MYC (9E10, Roche), FLAG
M2 (F1804, Sigma), HDAC1 (5356, c.s.).
Horseradish peroxidase-coupled secondary antibodies: goat
anti-mouse IgG and goat anti-rabbit IgG were from Dako
Cytomation or Dianova, rabbit anti chicken IgG (A-9046) was
Figure 5. Phosphorylation of Ser536 of p65 by CDK6/cyclin complexes contributes to activation of NF-kB-dependent transcription.
(A) HEK293IL-1R cells were transiently transfected with the indicated amounts (mg) of expression vectors and a NF-kB-dependent luciferase gene.
After 24 h cells were lyzed and luciferase activity was normalized for co-transfected SV40-promoter driven ß-galactosidase. The graph shows the
mean luciferase activity +/2 s.e.m. from three independent experiments performed in duplicates relative to the vector control. Expression of
cotransfected MYC-cyclin D1, v-cyclin derived from Kaposi’s sarcoma herpesvirus (MYC-v-cyclin) and HA-CDK6 was analyzed by immunoblotting
using anti MYC or anti CDK6 antibodies for all experiments in parallel. One representative blot is shown. (B) NF-kB p65-deficient MEFs stably
reconstituted with wild type p65 (2/2/wt) or the Ser536A mutant (2/2/Ser536A) as described [64] were transiently transfected with empty vector or
HA-CDK6 plus v-cyclin expression vectors. Cotransfected luciferase reporter genes were either controlled by three NF-kB binding sites (upper graph)
or alternatively by the cyclin D1 promoter (lower graph). After 24 h cells were lyzed, luciferase activity was determined and normalized for co-
transfected SV40-promoter driven ß-galactosidase activity. Shown is the mean luc. activity +/2 s.e.m. from three (lower graph) or four (upper graph)
independent experiments performed in duplicates relative to the vector control. The lower panel shows a representative immunoblot for the
detection of p65 wt and Ser536Ala mutant, p65 Ser536 phosphorylation and ectopically expressed CDK6. Asterisks indicate significant changes of
reporter gene activity.
doi:10.1371/journal.pone.0051847.g005
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from Sigma, IgG TrueBlot was from eBioscience. GST-fusion
proteins were expressed in E.coli BL21 and purified by standard
procedures.
Plasmids, Transfections, Stable Cell Lines and Reporter
Gene Assays
pCDNA3-CDK6-wt, pCDNA3-CDK6-S178P, pCDNA3-HIS-
Xpress-Cyclin D3 were from Pierre Roger [28], pGEX-based
expression vectors for GST-cyclin D1, D2 and D3 were from Yue
Xiong [37], pGEX-CDK6, pGEX-v(KSHV)-cyclin, pCDNA3-
MYC-v(KSHV)-cyclin, pCDNA3-MYC-cyclin D1, pCI-Neo-HA-
CDK6 were from Philip Kaldis [36]. The human cyclin D1
promoter(-1745)-pA3.Luc was from Richard G.Pestell [16]. For
generation of pSuper-Puro-shCDHK6 plasmids (Fig. 3C and
Fig. 4A), the following oligonucleotides were cloned into Bgl II/
Hind III sites of the vector:
shCDK6(1): forward primer, 59-GATCCCCAGTAGTG-
CATCGCGATCTAttcaagagaTAGATCGCGATGCACTACT-
TTTTTGGAAA-39, reverse primer, 59-AGCTTTTC-
CAAAAAAGTAGTGCATCGCGATCTAtctcttgaaTAGATCG-
CGATGCACTACTGGG. shCDK6(2): forward primer, 59-
GATCCCCGCAGAAATGTTTCGTAGAAttcaagagaTTCTA-
CGAAACATTTCTGCTTTTTGGAAA, reverse primer, 59-
AGCTTTTCCAAAAAGCAGAAATGTTTCGTAGAAtctcttga-
aTTCTACGAAACATTTCTGCGGG).
Sequences complementary to human CDK6 are shown in bold.
For generation of stable HeLa cell lines (Fig. 3C), pSuper-Puro-
shCDK6(2) or empty pSuper-Puro plasmids were transiently
transfected by the calcium phosphate method and pools of cells
selected and maintained in 1 mg/ml puromycin. The monoclonal
cell line K06 was obtained by limiting dilution.
Transient transfection of siRNA (sequences available on
request) against CDK6 was carried out in OptiMEM serum-free
medium (Invitrogen) using 50 ng siRNAduplexes and siLentFect
reagent (Biorad). After 6 h the medium was removed and cells
were cultured in serum-containing medium. Subsequently, 24 h
after transient transfection cells were washed twice with PBS and
stimulated with TNFa as indicated. GST-p65354-355 and NF-kB(3)-
Luc., have been described [4]. HEK293IL-1R or HeLa cells were
transiently transfected by the calcium phosphate method. p652/
2 cells were transfected using Rotifect (Roth) as described [4].
Equal amounts of plasmid DNA within each experiment were
obtained by adding empty vector. For determination of promoter
Figure 6. p65 Ser536 phosphorylation is increased in v-cyclin expressing B-cell lymphomas, pre-tumorigenic lymphoid organs and
further enhanced in thymic tumors. (A, B) Whole cell extracts were prepared from thymic (A) and splenic (B) lymphocytes isolated from non-
transgenic littermates and mice expressing FLAG-v-cyclin under the control of the Em promoter which targets v-cyclin expression to B- and T-cell
compartments [44,45]. Lymphocytes from control thymi and spleens, pre-tumorigenic thymi and spleens, as well as thymic tumors were analysed by
immunoblotting with antibodies against p65 phosphorylated at Ser536 (P-S536 p65), p65, CDK6, anti-FLAG (for v-cyclin) and cyclin D3. Anti-tubulin
was used as loading control. Numbers indicate individual mice. (C) H&E staining of tissue sections corresponding to thymic tissues as described
above.
doi:10.1371/journal.pone.0051847.g006
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activity, cells were seeded in 6-well plates and were transfected
with 0.25 mg of luciferase reporter plasmids and 0.5 to 1 mg of
pSV-ß-gal. ß-Galactosidase activity was determined using reagents
from Clontech to allow normalization of luciferase activity in
different transfections.
Cell Lysis and Immunoblotting
Whole cell extracts were prepared upon lysis of cells in Triton
cell lysis buffer (10 mM Tris, pH 7.05, 30 mM NaPPi, 50 mM
NaCl, 1% Triton X-100, 2 mM Na3VO4, 50 mM NaF, 20 mM
ß-glycerophosphate and freshly added 0.5 mM PMSF, 0.5 mg/ml
Leupeptin, 0.5 mg/ml pepstatin, 1 mg/ml microcystin) as previ-
ously described [66]. Cell lysates were subjected to SDS-PAGE on
6–9% gels and immunoblotting was performed as described
below. MDCK cells were washed twice with ice-cold PBS and
lysed in RIPA-buffer as described previously [67]. To prepare
cytosolic and nuclear fractions [68], cells were trypsinized, washed
twice with ice-cold PBS and harvested by centrifugation (5006g,
5 min, 4uC). Then cell pellets were resuspended in hypotonic
buffer. After centrifugation (2,3006g, 1 min, 4uC) supernatants
were used as cytoplasmic fractions. Nuclear pellets were washed
twice with hypotonic buffer and lysed in hypertonic buffer with
brief vortexing. Preparation of soluble nuclear extracts was carried
out by centrifugation (16,1006g, 5 min, 4uC).
Immunoblotting was performed essentially as described [4].
Proteins were separated on 6–10% SDS-PAGE and electropho-
retically transferred to PVDF membranes (Millipore). After
blocking with 2% or 5% dried milk in Tris-HCl-buffered saline/
0.05% Tween (TBST) for 1 h, membranes were incubated for 2–
24 h with primary antibodies, washed in TBST and incubated for
1–2 h with horseradish peroxidase-coupled secondary antibodies.
Proteins were detected by using enhanced chemiluminescence
(ECL) systems from Perbio, Pierce, Millipore or GE Healthcare on
x-ray films or the VersaDoc Imaging System (Biorad).
Purification of the p65 Ser536-phosphorylating Kinase
Three to four T175-cm2 flasks of HeLa cells were stimulated by
IL-1 (10 ng/ml) for 10 min at 37uC/5% CO2. Thereafter, cells
were harvested by scraping, followed by centrifugation (5 min,
5006g, 4uC), washed twice in ice-cold phosphate-buffered saline
containing 10 mM NaF and resuspended in 20 mM Tris, pH 8.5,
20 mM beta-glycerophosphate, 20 mM NaF, 0.1 mM Na3VO4,
0.5 mM EGTA, 0.5 mM EDTA, 0.1% (w/v) Nonidet P-40,
2 mM Dithiothreitol, 10 mM E64, 2.5 mg/ml leupeptin, 1 mM
phenylmethylsulfonyl fluoride, 1 mM pepstatin, and 400 nM
okadaic acid. Cells were broken mechanically by repeated rigorous
vortexing and intermediate incubation on ice for 30 min. Then
the lysate was cleared at 10,0006g (13,000 rpm) for 15 min at
4uC. Supernatants were frozen in liquid nitrogen and stored at
280uC. Lysate containing approximately 4–6 mg total protein
was diluted into 2.5 ml of buffer A (20 mM Tris, pH 8.5, 20 mM
ß-glycerophosphate, 20 mM NaF, 0.1 mM Na3VO4, 0.5 mM
EGTA, 0.5 mM EDTA, 0.05% Nonidet P-40, 2 mM dithiothre-
itol), filtered through an 0.2 mM membrane (Sartorius) and loaded
onto a 1 ml Resource Q column (GE Healthcare) equilibrated in
buffer A. After washing the column, proteins were eluted with a
linear salt gradient (0–0.75 M NaCl in 1 6 ml). 1 ml fractions were
collected, frozen (N2) and stored at 280uC until further use.
The kinase of interest eluted with an activity maximum at about
0.1 M NaCl. Active Fractions (fractions F5–F8) of four to six
ResourceQ-runs were pooled and prepared for hydrophobic
interaction chromatography conditions by slowly adding one
fourth of sample volume of starting buffer (0.48 M Tris/HCl,
pH 6.7, 4 M NaCl, 20 mM ß-glycerophosphate, 10 mM NaF,
4 mM DTT), resulting in a final sample pH of 7.3 and an initial
NaCl concentration at 1 M. The sample was filtered and applied
onto a 1 ml Phenyl-Sepharose HP column (GE Healthcare)
equilibrated with running buffer C (20 mM Tris/HCl, pH 7.3,
1 M NaCl, 20 mM mM ß-glycerophosphate, 20 mM NaF,
0.25 mM EGTA, 0.25 mM EDTA, 2 mM DTT). Elution of the
kinase was achieved by a decreasing NaCl- gradient (1 M to 0 M
NaCl in 16 ml) using Buffer D (Buffer C without NaCl). Peak
activity was observed at a NaCl concentration of approximately
0.4 M NaCl. Active fractions (H16–H19) of 10 lysates were pooled
and concentrated by ultrafiltration (vivaspin 2 (10,000 MWCO)
RC Sartorius Stedim) by the factor 12 related to the initial volume.
To prevent protein unspecific loss of protein the membrane of the
ultrafiltration device was coated with 5% (w/v) Triton X-100
according to manufacturers instructions. For sample preparation
prior to preparative SDS-PAGE further protein concentration was
performed by acetone precipitation (by adding 4 volume parts
acetone per one volume sample, followed by incubation at 220uC
for 4 h and a subsequent centrifugation (13,000 rpm, 4uC,
20 min)). For SDS-PAGE (Gel: 10% PAA) resulting pellets were
resuspended in reducing 1xSDS-PAGE-sample buffer, boiled for
23 min. and loaded onto the gel (loaded amount was the
equivalent of five lysates). Sypro Ruby stain of the gel was
performed overnight according to manufacturers protocol.
Detected protein bands were excised and detected by mass
spectrometry.
In vitro Kinase Assays
For the kinase assays, 10 ml of HIC fractions or 10 ml of
recombinant CDK6/cycD1 were mixed with 1 mg of GST-p65354-
551 in 10 ml T and 10 ml of kinase buffer (150 mM Tris, pH 7.4,
30 mM MgCl2, 600 mM ATP). After 30 min at 30uC reaction
mixtures were separated by SDS-PAGE and phosphorylation of
p65 was detected by immunoblotting with the anti P-Ser536
antibodies. Substrate loading was controlled by re-probing with
anti p65 antibodies.
For IP of HIC-purified material, 120 ml of pooled HIC fractions
16–19 were diluted to 500 ml with Resource Q buffer A, pH 7.3,
including 1% BSA, 0.05% NP-40, 0.2 mM DTT and 1 mg of
rabbit IgG or anti CDK6 antibody was added for 2 h at 4uC.
Thereafter samples were precipitated with 40 ml of pre-equilibrat-
ed protein G sepharose and washed 2x in 500 ml of IP buffer
including 0.2% NP-40, 1 mM DTT. Then, 1/5 of the sample was
removed for immunoblotting. Beads were spun down and
resuspended in 10 ml of IP buffer. 20 ml of kinase buffer including
1.5 mg of GST-p65354-551, 4 mCi
32P-ATP and 15 mM ATP. After
45 min at 30uC samples were separated by SDS-PAGE and
phosphorylated GST-p65 was detected by autoradiography.
For assessing the in vitro activites of CDK6/cyclin complexes,
HeLa cells were resuspended in cyclin-activating kinase (CAK)
buffer (80 mM Hepes, pH 7.4, 15 mM MgCl2, 1 mM Na3VO4,
10 mM NaF, 10 mM ß-glycerophosphate, 2 mM DTT, 1 mM
PMSF, Roche protease inhibitors). Cells were broken mechani-
cally by repeated rigorous vortexing and supernatants recovered
by centrifugation. 50 ml of lysate (250 mg) were mixed with 2 mg of
GST-CDK6 plus 2 mg of GST-cyclins in CAK buffer including
1 mM ATP and 0.1% NP-40 for 23 h at 30uC. GST-fusion
proteins were purified by addition of GSH sepharose for 30 min at
4uC, washed 3x and eluted in 100 ml of CAK buffer plus 10 mM
GSH for 15 min at 30uC. 10 ml of the eluate was mixed with 1 mg
of GST-p65354-551 in 20 ml kinase reaction buffer including
200 mM ATP. After incubation at 30uC for the indicated times,
proteins were separated by SDS-PAGE and phosphorylation of
GST-p65 was detected by immunoblotting.
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Further details on in vitro kinase assays for phosphorylation of
GST-p65354-551 are described in [4] and in [37].
Protein Identification by Tandem Mass Spectrometry
Sypro ruby-stained gel bands were excised with a scalpel, and
proteins were digested in gel with trypsin, using an Investigator
Progest robot (Genomic Solutions, Huntingdon, UK). Samples
were analyzed by high performance liquid chromatography
coupled to electrospray ionisation tandem mass spectrometry
(HPLC ESI MS/MS). HPLC was carried out on a CapLC liquid
chromatography system (Waters, ManchesterUK). Aliquots (6 mL)
of peptide mixtures were injected onto a Pepmap C18 column
(300 mm60.5 cm; LC Packings, Amsterdam, The Netherlands)
and eluted with an acetonitrile/0.1% formic acid gradient to the
nanoelectrospray source of a Q-Tof spectrometer (Micromass,
Manchester, UK) at a flow rate of 1 m/min. The spray voltage was
set to 3500V and data dependent MS/MS acquisitions were
performed on precursor peptides with charge states 2, 3, or 4 over
a survey mass range 440–1400 using argon collision gas. The
recorded product ion spectra were transformed into a singly
charged m/z axis using a maximum entropy method (MaxEnt3,
Waters, UK), and centroided peaklist (pkl) files were extracted
using the MassLynx component peptide auto (Waters, Manchester
UK). Proteins were identified by correlation of uninterpreted
spectra to entries in SwissProt (Release 2010_04: 516,081 entries)
using a local installation of Mascot (version 2.2: www.
matrixscience.com). MS/MS ion searches specified up to two
missed cleavages per peptide, a precursor mass tolerance of
60.5 Da and a fragment ion mass tolerance of 60.5 Da.
Carbamidomethylation of cysteines and methionine oxidation
were specified as fixed and variable modifications respectively.
Criteria for protein identification: MS/MS based peptide and
protein identifications were validated using Scaffold (Proteome
Software Inc., Portland, Oregon: version 3.01). Peptide identifi-
cations were accepted if they could be established at greater than
95.0% probability as specified by the Peptide Prophet algorithm
[69]. Protein Identifications were accepted if established at greater
than 99.0% probability and contained at least 2 matched peptides.
Protein probabilities were assigned by the Protein Prophet
algorithm [70].
RT-qPCR
1 mg of total RNA was prepared by column purification
(Qiagen) and transcribed into cDNA using Moloney murine
leukemia virus reverse transcriptase (MBI) in a total volume of
20 ml. 1–2 ml/well of this reaction mixture was used to amplify
cDNAs using assays on demand (ABI) and an ABI7500 Fast real
time PCR instrument. The threshold value ct for each individual
PCR product was calculated by the instrument’s software, and ct
values were normalized by subtracting the ct values obtained for ß-
actin. The resulting Dct values were then used to calculate relative
changes of mRNA expression as ratio (R) of mRNA expression of
stimulated/unstimulated cells according to the equation:
R= 22(Dct(stimulated)2Dct(unstimulated)).
Lentiviral Production and Transduction
Production of lentiviral supernatants and CDK6 silencing in
BC-3 cells were performed as described earlier [45].
Subcellular Fractionation and Immunoblotting
Subcellular fractionation of BC-3 cells was performed as
described earlier [71].
Em-v-cyclin Transgenic Mice and Analysis of Mouse
Lymphocytes
Em-v-cyclin transgenic mice were kindly provided by Emmy
Verschuren and Gerard Evan (Cancer Research Institute,
University of California) and were maintained as described earlier
[44,45]. Spleens from 5.5-week old pre-tumorigenic mice were
obtained by dissection. Tissue was disaggregated by pressing
through a 70 mm nylon mesh cell strainer (BD Falcon) in RPMI
containing 10% FCS to obtain a single cell suspension. Splenic
erythrocytes were eliminated by incubation for 5 min at room
temperature in ACK buffer (155 mM NH4Cl, 10 mM KHCO3,
and 0.1 mM EDTA, pH 7.8). Lymphocytes were pelleted and
washed once with PBS before lysis. Mouse lymphocytes were lysed
to Urea-Tris Buffer (UTB) (9 M Urea, 75 mM Tris-HCl, pH 7.5,
0.15 M 2-mercaptoethanol, complete proteinase inhibitor cocktail,
phosphatase inhibitory cocktail (PhosphoSTOP, Roche)), homog-
enized by sonication and cleared by centrifugation. Proteins (50 mg
of spleens and PEL cells, 75 mg of thymi) were fractionated by
SDS-PAGE and were transferred to nitrocellulose membranes.
Membranes were probed with antibodies as described above.
Statistics
Statistics were calculated by the Mann-Whitney Rank test or
paired t-test using Sigma Plot, version 11.0. Bands detected by
immunoblotting were quantified using ImageJ (http://rsbweb.nih.
gov/ij/).
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